Press Releases

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List)...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim...

Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist program Closed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide...